Eysuvis costs around $529 for a single 8.3 mL bottle without insurance, making it one of the pricier eye drops on the market. The high price comes down to a few reinforcing factors: it uses patented drug delivery technology, it has no generic equivalent, and its insurance coverage remains limited for many patients.
What Eysuvis Is and Why It Exists
Eysuvis is a corticosteroid eye drop approved by the FDA in October 2020 for the short-term treatment of dry eye disease, limited to two weeks of use. The active ingredient, loteprednol etabonate, isn’t new. It’s the same steroid found in Lotemax, which has been available for years and now has a generic version. What sets Eysuvis apart is how it delivers that steroid to your eye.
The drug was originally developed by Kala Pharmaceuticals using a proprietary system called AMPPLIFY, which wraps the steroid in mucus-penetrating nanoparticles. These tiny particles pass through the tear film without being broken down, allowing more of the drug to actually reach the surface of your eye. A single drop of Eysuvis delivers up to three times the concentration of loteprednol to the cornea and surrounding tissues compared to standard Lotemax gel. That improved delivery is the core of the product’s value proposition, and it’s the main reason the manufacturer prices it at a premium.
No Generic Competition
The biggest driver of Eysuvis’s price is the lack of a generic alternative. Standard loteprednol (the same steroid) is available in generic form through Lotemax, which brings its cost down. But because Eysuvis uses that patented nanoparticle delivery system, no other company can manufacture a generic version while the patent holds. Without competition, there’s no downward pressure on the price.
This is a common pattern in ophthalmology. A well-known active ingredient gets reformulated with new delivery technology, the new formulation earns its own patent protection, and the price resets at a brand-name level. Alcon, the large eye care company that acquired the U.S. rights to Eysuvis from Kala Pharmaceuticals in May 2022, now controls its pricing and distribution.
How It Compares to Similar Drops
On a per-unit basis, Eysuvis and brand-name Lotemax are surprisingly close in price (roughly $64 per milliliter for each). The difference shows up in the total bottle cost. A bottle of Eysuvis (8.3 mL at 0.25% concentration) runs about $529, while a bottle of Lotemax (5 mL at 0.5%) costs around $323. Generic loteprednol, of course, costs significantly less than either.
The practical question for most people is whether the improved drug delivery justifies paying brand-name prices when a generic version of the same steroid exists. That’s a conversation worth having with your eye doctor, especially if you’re paying out of pocket.
Insurance Coverage Is Hit or Miss
Part of the reason Eysuvis feels so expensive is that many patients end up paying full price or close to it. As of early 2022, about 70% of commercial insurance plans (covering roughly 118 million people) had added Eysuvis to their formularies. That sounds like broad coverage, but it still leaves a significant number of commercially insured patients without it.
Medicare coverage is much thinner. Only about 15% of Medicare lives had access to Eysuvis through select plans with major pharmacy benefit managers like Express Scripts, Prime Therapeutics, and Cigna. If your Medicare Part D plan doesn’t cover it, you’re looking at the full retail price. Even when plans do cover Eysuvis, it’s typically placed on a higher formulary tier, meaning your copay will be larger than it would be for a generic steroid drop.
Ways to Lower the Cost
Alcon offers a Patient Access Program that may reduce copay costs for eligible patients. There’s also an Eysuvis copay card available through the manufacturer. Eligibility and savings amounts vary, but you can check by calling 800-757-9195 or visiting the program’s website. These programs typically help commercially insured patients the most. If you’re uninsured or on Medicare, the savings may be more limited.
If cost is a barrier, it’s worth asking your eye doctor whether a standard loteprednol formulation or another anti-inflammatory drop could work for your situation. Eysuvis delivers more of the drug per drop, but for some patients, the older formulations may be effective enough at a fraction of the price.